Latest News: Conference Dates: 11th-13thApril, 2018 All the registered authors have to send the final PPT to before 11th April 2018 Acceptance Notification Starts From: 15-03-2018 Camera Ready Paper Submission: 25-03-2018 - (Extended to)31-03-2018 Early Registration Ends On: 25-03-2018 -(Extended to)31-03-2018 Late Registration Ends On: 02-04-2018

Invited Talk-III-Biomedical Engineering

Zinc Oxide Nanoparticles: A promising Nanomedicine for Future Therapy


Zinc oxide (ZnO) nanoparticles nanoparticles offer considerable promise in biomedical applications, such as drug delivery, geneand antigen delivery,antimicrobial applications,biosensor,tissue engineering etc. ZnOnanomaterialshave been studied for bioimaging purposes due to their luminescence properties. Apart from versatile biological applications of ZnO, we have demonstrated the pro-angiogenic properties of ZnOnanoflowers (ZONF), observed by variousin vitro and in vivoangiogenesis assays. Angiogenesis is a vital process which deals with the generation of new blood vessels from pre-existing vasculature and well-known to regulate various physiological as well as pathophysiolgical processes. Recently, we reported that ZONF induced the production of reactive oxygen species (ROS) that might augment the phosphorylation of different downstream signaling molecules such as p38MAPK, Akt and eNOS. Additionally, activation of eNOS elevated the intracellular level of NO, triggering angiogenesis in cGMP (cyclic guanosine monophosphate) dependent fashion.

More recently, we have also investigated the neuritogenic and neuroprotective properties of this pro-angiogenic ZONF. The neuritogenic activity of ZONF was initially investigated in Neuro 2a (mouse neuroblastoma) cells and the results showed the enhancement of neurite length of cells in presence of ZONF in both dose and time dependent manner. The neuritogenic activity was further confirmed by western blot analysis and PCR analysis. Finally, the neuroprotective efficacy of nanoparticles was evaluated against BCCAO (bilateral common carotid artery occlusion) induced global cerebral ischemia (stroke) in Fischer rat. Behavioural studies exhibited faster recovery of ZONF administered ischemic rats compared to control experiment (TE buffer), suggesting the therapeutic efficacy of nanoparticles in cerebral ischemia. Considering the pro-angiogenic and neuritogenicactivity of ZONF, it can be useful for the development of an efficient and effective alternative strategy for the treatment ofvarious ischemic diseases (ischemic heart, limb and brain).


Chittaranjan Patra received his B.Sc (1995) and M.Sc (1997) in Chemistry from the University of Burdwan, W.B. He was awarded the “Dr. Mrigendranath Ghosh Gold Medal” for obtaining first class and first rank in B.Sc Chemistry (Hons) Examination in 1995 from The University of Burdwan, India. He completed his Ph.D. in Chemistry in 2003 (as CSIR Fellow: April 1998- March 2003) from National Chemical Laboratory (NCL), Pune. Thereafter, he received his postdoctoral experience (March 2003-October 2004) as ‘Nanotechnologist’ from Bar-Ilan University, Ramat-Gan, Israel. After that he moved to Mayo Clinic, Department of Biochemistry and Molecular Biology in October 2004 as postdoc followed by Assistant Professor in the same Department. Here Dr. Patra explored the field of nanobiotechnology for cancer and angiogenesis. Dr. Patra moved to CSIR-IICT-Hyderabad in 2010 after receiving prestigious Ramnujan Fellowship, from DST-New Delhi. Currently, Dr. Patra is working as Principal Scientist at Department of Applied Biology, CSIR-Indian Institute of Chemical Technology (IICT) and his research group is pursuing various nanomedicine research projects aimed at developing advanced nanomaterials and nanoparticles based drug delivery systems (DDS) for treatment of cancer, cardiovascular and ischemic disease.

He has 96 peer-reviewed publications in high impact international journals (Google citations: 3735, h-index: 32 & i-index: 64), 12 book chapters and 5 patents (granted/pending/submitted) to his credit. Currently, Dr. Patra is guiding 4 Ph.D. students, 2 Project Assistants and 2 dissertation students of B.Eng. Two Ph.D. students have been awarded and one submitted thesis under his supervision. Additionally, he already trained 21 dissertations student of M.Sc., M.Pharm., M.Tech. & B.Tech. Dr. Patra served as invited reviewer for more than 40 various International journals including Advanced Drug Delivery Review, Biomaterials, Nanoscale, ChemComm, Nanomedicine, Organic Letters, nanotechnology etc. Dr. Patra is the member of ACS, AACR, AAAS, CRSI, ISCA, ISCB, CBS-India, ABAP, ICS and he has already delivered 33-invited lectures, 1 Plenary Lecture and 1 Key Note Address. He served as Editorial Board Member of ‘Nanoscience and Nanotechnology’, ‘Gene Therapy and Molecular Biology (GTMB)’ and ‘Journal of Nanomedicine & Nanotechnology’. Apart from ‘Ramanujan Fellowship’ Dr. Patra received, ‘Young Investigator Award’, Michael A. O’Connor Travel Award’ from Mayo Clinic angiogenesis symposium, QRS Best Scientist Award from CSIR-IICT, and DR. DS Bhakuni Award from Indian Chemical Society. The World Science Congress (WSC), Kolkata felicitated Dr. Patra as ‘FLAME OF SCIENCE’ for lifetime contribution and excellence for the Noble Cause of Science.